Metabolic reprogramming of the tumor

Oncogene

Volumn 31, Issue 36, 2012, Pages 3999-4011

  Ferreira, L M R ^a   Hebrant, A ^b   Dumont, J E ^b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Cancer; evolution; metabolism; microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT;

BIOENERGY; CANCER CELL; CANCER GENETICS; CANCER INVASION; CANCER RESEARCH; CARCINOGENESIS; CELL METABOLISM; EPIGENETICS; GENETIC SELECTION; HUMAN; METASTASIS; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; ENERGY METABOLISM; GENES, NEOPLASM; GLYCOLYSIS; HISTORY, 20TH CENTURY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84866127673     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.576     Document Type: Review

References (178)

1. 2 mediate glucose deprivation-induced cytotoxicity and oxidative stress in human cancer cells. J Biol Chem 280: 4254-4263.
2. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang JX, Chen J et al. (2001). Constitutive expression of hypoxia-inducible factor-1 alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61: 6548-6554.
3. Alexander S, Koehl GE, Hirschberg M, Geissler EK, Friedl P. (2008). Dynamic imaging of cancer growth and invasion: a modified skinfold chamber model. Histochem Cell Biol 130: 1147-1154.
4. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM. (1998). Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392: 405-408.
5. Atkinson DE. (1968). The energy charge of the adenylate pool as a regulatory parameter. Interaction with feedback modifiers. Biochemistry 7: 4030-4034.
6. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. (2005). ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24: 6314-6322.
7. Bensaad K, Tsuruta A, Selak MA, Vidal MNC, Nakano K, Bartrons R et al. (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107-120.
8. Berardi MJ, Fantin VR. (2011). Survival of the fittest: metabolic adaptations in cancer. Curr Opin Genet Dev 21: 59-66.
9. -2 availability on human cancer. Nat Rev Cancer 8: 967-975.
10. Berx G, van Roy F. (2009). Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol 1: a003129.
11. Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V et al. (2006). Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res 66: 6087-6096.
12. Boveri T. (1914). Zur Frage der Entstehung maligner Tumoren. Gustav Fischer: Jena.
13. Boyland E, Boyland ME. (1935). XXXV. Studies in tissue metabolism: VIII. The effect of fumarate and succinate on tumour respiration. Biochem J30: 224-226.
14. Brahimi-Horn MC, Bellot G, Pouyssegur J. (2011). Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev 21: 67-72.
15. Bruick RK, McKnight SL. (2001). A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340.
16. Burk D, Schade AL. (1956). On respiratory impairment in cancer cells. Science 124: 270-272.
17. Cai Z, Semenza GL. (2005). PTEN activity is modulated during ischemia and reperfusion: involvement in the induction and decay of preconditioning. Circ Res 97: 1351-1359.
18. Cairns RA, Harris IS, Mak TW. (2011). Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95.
19. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA et al. (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467: 1109-1113.
20. Cannito S, Novo E, di Bonzo LV, Busletta C, Colombatto S, Parola M. (2010). Epithelial-mesenchymal transition: from molecular mechanisms, redox regulation to implications in human health and disease. Antioxid Redox Signal 12: 1383-1430.
21. Carnero A, Hudson JD, Price CM, Beach DH. (2000). p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol 2: 148-155.
22. Carrel A, Ebeling AH. (1921). Age and multiplication of fibroblasts. J Exp Med 34: 599-623.
23. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. (2008). Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452: 181-186.
24. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. (2003). Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 17: 1195-1214.
25. Cori CF, Cori GT. (1925a). The carbohydrate metabolism of tumors. II. Changes in the sugar, lactic acid, and co-combing power of blood passing through a tumor. J Biol Chem 65: 397-405.
26. Cori CF, Cori GT. (1925b). The carbohydrate metabolism of tumors. I. The free sugar, lactic acid, and glycogen content of malignant tumors. J Biol Chem 64: 11-22.
27. Cramer W. (1926). A British Medical Association Lecture on the New Outlook on Cancer. Br Med J 1: 175-180.
28. D'Errico I, Salvatore L, Murzilli S, Lo Sasso G, Latorre D, Martelli N et al. (2011). Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1alpha) is a metabolic regulator of intestinal epithelial cell fate. Proc Natl Acad Sci USA 108: 6603-6608.
29. Dang CV, Kim JW, Gao P, Yustein J. (2008). The interplay between MYC and HIF in cancer. Nat Rev Cancer 8: 51-56.
30. David CJ, Chen M, Assanah M, Canoll P, Manley JL. (2010). HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463: 364-368.
31. De Bari L, Chieppa G, Marra E, Passarella S. (2010). L-lactate metabolism can occur in normal and cancer prostate cells via the novel mitochondrial L-lactate dehydrogenase. Int J Oncol 37: 1607-1620.
32. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S et al. (2007). Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104: 19345-19350.
33. Droge W, Eck HP, Mihm S. (1992). HIV-induced cysteine deficiency and T-cell dysfunction\a rationale for treatment with N-acetylcys-teine. Immunol Today 13: 211-214.
34. Eck HP, Drings P, Droge W. (1989). Plasma glutamate levels, lymphocyte reactivity and death rate in patients with bronchial carcinoma. J Cancer Res Clin Oncol 115: 571-574.
35. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR et al. (2004). Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899.
36. Eng CH, Yu K, Lucas J, White E, Abraham RT. (2010). Ammonia derived from glutaminolysis is a diffusable regulator of autophagy. Sci Signal 3: ra31.
37. Erecinska M, Deas J, Silver IA. (1995). The effect of pH on glycolysis and phosphofructokinase activity in cultured cells and synapto-somes. J Neurochem 65: 2765-2772.
38. Evans T, Rosenthal ET, Youngblom J, Distel D, Hunt T. (1983). Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 33: 389-396.
39. Fearon ER, Vogelstein B. (1990). A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
40. Feinberg AP, Ohlsson R, Henikoff S. (2006). The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33.
41. Feng Z, Levine AJ. (2010). The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 20: 427-434.
42. Ferreira LMR. (2010). Cancer metabolism: the Warburg effect today. Exp Mol Pathol 89: 372-380.
43. Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M et al. (2007). Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109: 3812-3819.
44. Flier JS, Mueckler MM, Usher P, Lodish HF. (1987). Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 235: 1492-1495.
45. Floor S, van Staveren WC, Larsimont D, Dumont JE, Maenhaut C. (2011). Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating- cancer stem cells: distinct, overlapping or same populations. Oncogene 30: 4609-4621.
46. Fogal V, Richardson AD, Karmali PP, Scheffler IE, Smith JW, Ruoslahti E. (2010). Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. Mol Cell Biol 30: 1303-1318.
47. Folkman J. (2003). Fundamental concepts of the angiogenic process. Curr Mol Med 3: 643-651.
48. Friedl P, Gilmour D. (2009). Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol 10: 445-457.
49. Funes JM, Quintero M, Henderson S, Martinez D, Qureshi U, Westwood C et al. (2007). Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci USA 104: 6223-6228.
50. Gallagher SM, Castorino JJ, Wang D, Philp NJ. (2007). Mono-carboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res 67: 4182-4189.
51. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T et al. (2009). c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458: 762-765.
52. Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V et al. (2007). HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12: 230-238.
53. Gatenby RA, Gillies RJ. (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4: 891-899.
54. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL. (2002). Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 62: 3909-3913.
55. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E. (2009). Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 11: 1287-1296.
56. Gil J, Kerai P, Lleonart M, Bernard D, Cigudosa JC, Peters G et al. (2005). Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res 65: 2179-2185.
57. Gladden LB. (2004). Lactate metabolism: a new paradigm for the third millennium. J Physiol 558: 5-30.
58. Goldblatt H, Cameron G. (1953). Induced malignancy in cells from rat myocardium subjected to intermittent anaerobiosis during long propagation in vitro. J Exp Med 97: 525-552.
59. Guppy M. (2002). The hypoxic core: a possible answer to the cancer paradox. Biochem Biophys Res Commun 299: 676-680.
60. Guppy M, Greiner E, Brand K. (1993). The role of the Crabtree effect and an endogenous fuel in the energy metabolism of resting and proliferating thymocytes. Eur J Biochem 212: 95-99.
61. Hahn WC, Weinberg RA. (2002). Modelling the molecular circuitry of cancer. Nat Rev Cancer 2: 331-341.
62. Halabe Bucay A. (2009). Hypothesis provedycitric acid (citrate) does improve cancer: a case of a patient suffering from medullary thyroid cancer. Med Hypotheses 73: 271.
63. Hammond EM, Giaccia AJ. (2005). The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun 331: 718-725.
64. Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell 144: 646-674.
65. Hansemann D. (1890). Uber asymmetrische Zelltheilung in Epithelh-resbsen und deren biologische bedeutung. Virchows Arch A Pathol Anat Histopathol 119: 299-326.
66. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D et al. (2005). ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8: 311-321.
67. Holley RW, Kiernan JA. (1974). Control of the initiation of DNA synthesis in 3T3 cells: low-molecular-weight nutrients. Proc Natl Acad Sci USA 71: 2942-2945.
68. Hollstein M, Sidransky B, Vogelstein B, Harris CC. (1991). p53 mutations in human cancers. Science 253: 49-53.
69. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab 14: 131-142.
70. Huebner RJ, Todaro GJ. (1969). Oncogenes of RNA tumor viruses as determinants of cancer. Proc Natl Acad Sci USA 64: 1087-1094.
71. Ikeda E, Achen MG, Breier G, Risau W. (1995). Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 270: 19761-19766.
72. Imai T, Horiuchi A, Wang C, Oka K, Ohira S, Nikaido T et al. (2003). Hypoxia attenuates the expression of E-cadherin via upregulation of SNAIL in ovarian carcinoma cells. Am J Pathol 163: 1437-1447.
73. Isidoro A, Martinez M, Fernandez PL, Ortega AD, Santamaria G, Chamorro M et al. (2004). Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J 378: 17-20.
74. Johnston LA. (2009). Competitive interactions between cells: death, growth, and geography. Science 324: 1679-1682.
75. Jones RG. (2009). Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 23: 537-548.
76. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y et al. (2005). AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293.
77. Kahn BB, Alquier T, Carling D, Hardie DG. (2005). AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25.
78. Kiebish MA, Han XL, Cheng H, Chuang JH, Seyfried TN. (2008). Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer. J Lipid Res 49: 2545-2556.
79. Kim J, Yu W, Kovalski K, Ossowski L. (1998). Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94: 353-362.
80. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. (2007). Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexoki-nase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 27: 7381-7393.
81. Kim JW, Zeller KI, Wang Y, Jegga AG, Aronow BJ, O'Donnell KA et al. (2004). Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol 24: 5923-5936.
82. King A, Selak MA, Gottlieb E. (2006). Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 25: 4675-4682.
83. Klimova T, Chandel NS. (2008). Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Diff 15: 660-666.
84. Knox WE, Horowitz ML, Friedell GH. (1969). The proportionality of glutaminase content to growth rate and morphology of rat neoplasms. Cancer Res 29: 669-680.
85. Knox WE, Tremblay GC, Spanier BB, Friedell GH. (1967). Glutaminase activities in normal and neoplastic tissues of the rat. Cancer Res 27: 1456-1458.
86. Knudson Jr AG. (1971). Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820-823.
87. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G et al. (2005). Glycolytic enzymes can modulate cellular life span. Cancer Res 65: 177-185.
88. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. (2004). HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 23: 1949-1956.
89. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. (2006). Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res 66: 632-637.
90. Krebs HA, Johnson WA. (1937). The role of citric acid in intermediate metabolism in animal tissues. Enzymologia 4: 148-156.
91. Kroemer G, Pouyssegur J. (2008). Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482.
92. Lardner A. (2001). The effects of extracellular pH on immune function. J Leukoc Biol 69: 522-530.
93. Lebedeva MA, Eaton JS, Shadel GS. (2009). Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis. Biochim Biophys Acta 1787: 328-334.
94. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY, Lee EY. (1987). Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235: 1394-1399.
95. Levine AJ. (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
96. Li F, Wang Y, Zeller KI, Potter JJ, Wonsey DR, O'Donnell KA et al. (2005). Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol 25: 6225-6234.
97. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF et al. (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679.
98. Lin CM, Abcouwer SF, Souba WW. (1999). Effect of dietary glutamate on chemotherapy-induced immunosuppression. Nutrition 15: 687-696.
99. Loeffler DA, Juneau PL, Masserant S. (1992). Influence of tumour physico-chemical conditions on interleukin-2-stimulated lymphocyte proliferation. Br J Cancer 66: 619-622.
100. Lowe SW, Cepero E, Evan G. (2004). Intrinsic tumour suppression. Nature 432: 307-315.
101. Luo J, Kuo MH. (2009). Linking nutrient metabolism to epigenetics. Cell Sci Rev 6: 49-54.
102. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R et al. (2011). Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145: 732-744.
103. Lynen F. (1942). Die Rolle der Phosphorsaure bei Dehydrierungsvor-gangen und ihre biologische Bedeutung. Naturwissenschaften 30: 398-406.
104. Madsen CD, Sahai E. (2010). Cancer dissemination\lessons from leukocytes. Dev Cell 19: 13-26.
105. Mandriota SJ, Pepper MS. (1998). Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 83: 852-859.
106. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
107. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ. (1996). Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 14: 176-186.
108. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O et al. (2006). p53 regulates mitochondrial respiration. Science 312: 1650-1653.
109. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E et al. (2010). Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2: 31ra34.
110. Miles FL, Pruitt FL, van Golen KL, Cooper CR. (2008). Stepping out of the flow: capillary extravasation in cancer metastasis. Clin Exp Metastasis 25: 305-324.
111. Milovanova TN, Bhopale VM, Sorokina EM, Moore JS, Hunt TK, Hauer-Jensen M et al. (2008). Lactate stimulates vasculogenic stem cells via the thioredoxin system and engages an autocrine activation loop involving hypoxia-inducible factor 1. Mol Cell Biol 28: 6248-6261.
112. Mitchell P. (1961). Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. Nature 191: 144-148.
113. Miyamoto S, Murphy AN, Brown JH. (2008). Akt mediates mitochondrial protection in cardiomyocytes through phosphoryla-tion of mitochondrial hexokinase-II. Cell Death Differ 15: 521-529.
114. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. (2008). Autophagy fights disease through cellular self-digestion. Nature 451: 1069-1075.
115. Newberne PM. (2002). Choline deficiency associated with diethanola-mine carcinogenicity. Toxicol Sci 67: 1-3.
116. Oakhill JS, Steel R, Chen ZP, Scott JW, Ling N, Tam S et al. (2011). AMPK is a direct adenylate charge-regulated protein kinase. Science 332: 1433-1435.
117. Okoshi R, Ozaki T, Yamamoto H, Ando K, Koida N, Ono S et al. (2008). Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem 283: 3979-3987.
118. Oliva CR, Nozell SE, Diers A, McClugage 3rd SG, Sarkaria JN, Markert JM et al. (2010). Acquisition of temozolomide chemore-sistance in gliomas leads to remodeling of mitochondrial electron transport chain. J Biol Chem 285: 39759-39767.
119. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M et al. (2000). Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 275: 21797-21800.
120. Pasteur L. (1876). Experiences et vues nouvelles sur la nature des fermentations. Compt Rend Acad Sci 52: 1260-1264.
121. Pauwels EKJ, Sturm EJC, Bombardieri E, Cleton FJ, Stokkel MPM. (2000). Positron-emission tomography with [F-18]fluorodeoxyglu-cose Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol 126: 549-559.
122. Pinner S, Jordan P, Sharrock K, Bazley L, Collinson L, Marais R et al. (2009). Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res 69: 7969-7977.
123. Pouyssegur J, Dayan F, Mazure NM. (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443.
124. Racker E, Spector M. (1981). Warburg effect revisited\merger of biochemistry and molecular biology. Science 213: 303-307.
125. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Moreno-Sanchez R. (2010). Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med 31: 29-59.
126. Ramos-Montoya A, Lee W-NP, Bassilian S, Lim S, Trebukhina RV, Kazhyna MV et al. (2006). Pentose phosphate cycle oxidative and nonoxidative balance: a new vulnerable target for overcoming drug resistance in cancer. Int J Cancer 119: 2733-2741.
127. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q et al. (2000). Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14: 34-44.
128. Rempel A, Bannasch P, Mayer D. (1994). Differences in expression and intracellular-distribution of hexokinase isoenzymes in rat-liver cells of different transformation stages. Biochim Biophys Acta 1219: 660-668.
129. Reshkin SJ, Bellizzi A, Caldeira S, Albarani V, Malanchi I, Poignee M et al. (2000). Na+/H+ exchanger-dependent intracellular alkalini-zation is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes. FASEB J 14: 2185-2197.
130. Rischin D, Peters L, Fisher R, Macann A, Denham J, Poulsen M et al. (2005). Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23: 79-87.
131. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K et al. (2010). Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 28: 2989-2995.
132. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. (2005). Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434: 113-118.
133. Ronzoni E, Ehrenfest E. (1936). The effect of dinitrophenol on the metabolism of frog muscle. J Biol Chem 15: 749-768.
134. Samudio I, Fiegl M, Andreeff M. (2009). Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res 69: 2163-2166.
135. Santamaria G, Martinez-Diez M, Fabregat I, Cuezva JM. (2006). Efficient execution of cell death in non-glycolytic cells requires the generation of ROS controlled by the activity of mitochondrial H+-ATP synthase. Carcinogenesis 27: 925-935.
136. Schulz TJ, Thierbach R, Voigt A, Drewes G, Mietzner B, Steinberg P et al. (2006). Induction of oxidative metabolism by mitochondrial frataxin inhibits cancer growth: Otto Warburg revisited. J Biol Chem 281: 977-981.
137. Schuman VL, Levitt SH, Song CW. (1982). The radioprotective effect of 5-thio-D-glucose on normal tissues in vivo. Int J Radiat Oncol Biol Phys 8: 589-591.
138. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. (2004). The tumor suppressor p53 downregulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 64: 2627-2633.
139. Semenza GL. (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
140. Semenza GL. (2009). Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 19: 12-16.
141. Semenza GL. (2010). HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20: 51-56.
142. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA et al. (1997). c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 94: 6658-6663.
143. Shin YK, Yoo BC, Chang HJ, Jeon E, Hong SH, Jung MS et al. (2005). Downregulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 65: 3162-3170.
144. Song CW, Sung JH, Clement JJ, Levitt SH. (1978). Cytotoxic effect of 5-thio-D-glucose on chronically hypoxic cells in multicell spheroids. Br J Cancer Suppl 3: 136-140.
145. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN et al. (2008). Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118: 3930-3942.
146. Staal SP. (1987). Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 84: 5034-5037.
147. Stehelin D, Guntaka RV, Varmus HE, Bishop JM. (1976). Purification of DNA complementary to nucleotide sequences required for neoplastic transformation of fibroblasts by avian sarcoma viruses. J Mol Biol 101: 349-365.
148. Stern R, Shuster S, Neudecker BA, Fromby B. (2002). Lactate stimulates fibroblast expression of hyaluronan and CD44: the Warburg effect revisited. Exp Cell Res 276: 24-31.
149. Stewart TJ, Abrams SI. (2008). How tumours escape mass destruction. Oncogene 27: 5894-5903.
150. Tennant DA, Duran RV, Gottlieb E. (2010). Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10: 267-277.
151. Thangaraju M, Gopal E, Martin PM, Ananth S, Smith SB, Prasad PD et al. (2006). SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res 66: 11560-11564.
152. Thierbach R, Schulz TJ, Isken F, Voigt A, Mietzner B, Drewes G et al. (2005). Targeted disruption of hepatic frataxin expression causes impaired mitochondrial function, decreased life span and tumor growth in mice. Hum Mol Genet 14: 3857-3864.
153. Thiery JP. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454.
154. Thiery JP, Acloque H, Huang RY, Nieto MA. (2009). Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
155. Thiery JP, Sleeman JP. (2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142.
156. Thomlinson RH, Gray LH. (1955). The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9: 539.
157. Tijo KH, Levan A. (1956). The chromosome number of man. Hereditas 42: 1-6.
158. Toffoli S, Michiels C. (2008). Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours. FEBS J 275: 2991-3002.
159. Tubiana M, Koscielny S. (2008). On clonogenic tumour cells and metastasis-forming cells. Nat Rev Cancer 8: 990.
160. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D et al. (2010). Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329: 1492-1499.
161. Varum S, Momcilovic O, Castro C, Ben-Yehudah A, Ramalho-Santos J, Navara CS. (2009). Enhancement of human embryonic stem cell pluripotency through inhibition of the mitochondrial respiratory chain. Stem Cell Res 3: 142-156.
162. Warburg O. (1923). Tests on surviving carcinoma cultures. Biochem-ische Zeitschrift 142: 317-333.
163. Warburg O. (1929). Is aerobic glycolysis specific to tumours? Biochemische Zeitschrift 204: 482-483.
164. Warburg O. (1930). Note on the metabolism of tumours. Biochemische Zeitschrift 228: 257-258.
165. Warburg O. (1956a). On the origin of cancer cells. Science 123: 309-314.
166. Warburg O. (1956b). On respiratory impairment in cancer cells. Science 124: 269-270.
167. Warburg O, Hiepler E. (1952). Versuche mit Ascites-Tumorzellen. Z Naturforsch 7b: 193-194.
168. Warburg O, Minami S. (1923). Tests on surviving carcinoma cultures. Klinische Wochenschrift 2: 776-777.
169. Warburg O, Posener K, Negelein E. (1924). On the metabolism of carcinoma cells. Biochemische Zeitschrift 152: 309-344.
170. Warburg O, Wind F, Negelein E. (1927). The metabolism of tumors in the body. J Gen Physiol 8: 519-530.
171. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA et al. (2010). The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17: 225-234.
172. Weinhouse S. (1956). On respiratory impairment in cancer cells. Science 124: 267-269.
173. Weinhouse S. (1972). Glycolysis, respiration, and anomalous gene expression in experimental hepatomas: GHA Clowes memorial lecture. Cancer Res 32: 2007-2016.
174. Wenner CE, Weinhouse S. (1953). Metabolism of neoplastic tissue. III. Diphosphopyridine nucleotide requirements for oxidations by mitochondria of neoplastic and non-neoplastic tissues. Cancer Res 13: 21-26.
175. Williams AC, Collard TJ, Paraskeva C. (1999). An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. Oncogene 18: 3199-3204.
176. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. (2008). Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2: 333-344.
177. Wu KJ, Zeng J, Zhu GD, Zhang LL, Zhang D, Li L et al. (2009). Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacol Sin 30: 1162-1168.
178. Yalcin A, Telang S, Clem B, Chesney J. (2009). Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphospha-tases in cancer. Exp Mol Pathol 86: 174-179.